123 related articles for article (PubMed ID: 1732531)
1. Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors.
Doherty AM; Sircar I; Kornberg BE; Quin J; Winters RT; Kaltenbronn JS; Taylor MD; Batley BL; Rapundalo SR; Ryan MJ
J Med Chem; 1992 Jan; 35(1):2-14. PubMed ID: 1732531
[TBL] [Abstract][Full Text] [Related]
2. Renin inhibitors containing esters at the P2-position. Oral activity in a derivative of methyl aminomalonate.
Repine JT; Himmelsbach RJ; Hodges JC; Kaltenbronn JS; Sircar I; Skeean RW; Brennan ST; Hurley TR; Lunney E; Humblet CC
J Med Chem; 1991 Jul; 34(7):1935-43. PubMed ID: 2066966
[TBL] [Abstract][Full Text] [Related]
3. New inhibitors of human renin that contain novel replacements at the P2 site.
Doherty AM; Kaltenbronn JS; Hudspeth JP; Repine JT; Roark WH; Sircar I; Tinney FJ; Connolly CJ; Hodges JC; Taylor MD
J Med Chem; 1991 Apr; 34(4):1258-71. PubMed ID: 1901910
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors.
Patt WC; Hamilton HW; Taylor MD; Ryan MJ; Taylor DG; Connolly CJ; Doherty AM; Klutchko SR; Sircar I; Steinbaugh BA
J Med Chem; 1992 Jul; 35(14):2562-72. PubMed ID: 1635057
[TBL] [Abstract][Full Text] [Related]
5. Rational design and synthesis of selective BACE-1 inhibitors.
Brady SF; Singh S; Crouthamel MC; Holloway MK; Coburn CA; Garsky VM; Bogusky M; Pennington MW; Vacca JP; Hazuda D; Lai MT
Bioorg Med Chem Lett; 2004 Feb; 14(3):601-4. PubMed ID: 14741251
[TBL] [Abstract][Full Text] [Related]
6. Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation.
Rao CM; Scarborough PE; Kay J; Batley B; Rapundalo S; Klutchko S; Taylor MD; Lunney EA; Humblet CC; Dunn BM
J Med Chem; 1993 Sep; 36(18):2614-20. PubMed ID: 8410973
[TBL] [Abstract][Full Text] [Related]
7. Renin inhibitors containing new P1-P1' dipeptide mimetics with heterocycles in P1'.
Raddatz P; Jonczyk A; Minck KO; Rippmann F; Schittenhelm C; Schmitges CJ
J Med Chem; 1992 Sep; 35(19):3525-36. PubMed ID: 1404233
[TBL] [Abstract][Full Text] [Related]
8. Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics.
Williams PD; Perlow DS; Payne LS; Holloway MK; Siegl PK; Schorn TW; Lynch RJ; Doyle JJ; Strouse JF; Vlasuk GP
J Med Chem; 1991 Mar; 34(3):887-900. PubMed ID: 2002469
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: prime side chromane-containing inhibitors.
Ng RA; Sun M; Bowers S; Hom RK; Probst GD; John V; Fang LY; Maillard M; Gailunas A; Brogley L; Neitz RJ; Tung JS; Pleiss MA; Konradi AW; Sham HL; Dappen MS; Adler M; Yao N; Zmolek W; Nakamura D; Quinn KP; Sauer JM; Bova MP; Ruslim L; Artis DR; Yednock TA
Bioorg Med Chem Lett; 2013 Aug; 23(16):4674-9. PubMed ID: 23856050
[TBL] [Abstract][Full Text] [Related]
10. Non-peptide renin inhibitors containing 2-(((3-phenylpropyl)phosphoryl)oxy)alkanoic acid moieties as P2-P3 replacements.
Raddatz P; Minck KO; Rippmann F; Schmitges CJ
J Med Chem; 1994 Feb; 37(4):486-97. PubMed ID: 8120867
[TBL] [Abstract][Full Text] [Related]
11. Novel renin inhibitors containing (2S,3S,5S)-2-amino-1-cyclohexyl-6-methyl-3,5-heptanediol fragment as a transition-state mimic at the P1-P1' cleavage site.
Yamada Y; Ando K; Ikemoto Y; Tada H; Shirakawa E; Inagaki E; Shibata S; Nakamura I; Hayashi Y; Ikegami K; Uchida I
Chem Pharm Bull (Tokyo); 1997 Oct; 45(10):1631-41. PubMed ID: 9353891
[TBL] [Abstract][Full Text] [Related]
12. Renin inhibitors containing alpha-heteroatom amino acids as P2 residues.
Repine JT; Kaltenbronn JS; Doherty AM; Hamby JM; Himmelsbach RJ; Kornberg BE; Taylor MD; Lunney EA; Humblet C; Rapundalo ST
J Med Chem; 1992 Mar; 35(6):1032-42. PubMed ID: 1552498
[TBL] [Abstract][Full Text] [Related]
13. Discovery of non-peptidic P2-P3 butanediamide renin inhibitors with high oral efficacy.
Simoneau B; Lavallée P; Anderson PC; Bailey M; Bantle G; Berthiaume S; Chabot C; Fazal G; Halmos T; Ogilvie WW; Poupart MA; Thavonekham B; Xin Z; Thibeault D; Bolger G; Panzenbeck M; Winquist R; Jung GL
Bioorg Med Chem; 1999 Mar; 7(3):489-508. PubMed ID: 10220035
[TBL] [Abstract][Full Text] [Related]
14. Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1' Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions.
Sawyer TK; Pals DT; Mao B; Staples DJ; de Vaux AE; Maggiora LL; Affholter JA; Kati W; Duchamp D; Hester JB
J Med Chem; 1988 Jan; 31(1):18-30. PubMed ID: 3275777
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core.
Wångsell F; Gustafsson K; Kvarnström I; Borkakoti N; Edlund M; Jansson K; Lindberg J; Hallberg A; Rosenquist A; Samuelsson B
Eur J Med Chem; 2010 Mar; 45(3):870-82. PubMed ID: 20036448
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent BACE-1 inhibitors containing a new hydroxyethylene (HE) scaffold: exploration of P1' alkoxy residues and an aminoethylene (AE) central core.
Björklund C; Adolfsson H; Jansson K; Lindberg J; Vrang L; Hallberg A; Rosenquist S; Samuelsson B
Bioorg Med Chem; 2010 Feb; 18(4):1711-23. PubMed ID: 20122837
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of potent macrocyclic renin inhibitors.
Sund C; Belda O; Wiktelius D; Sahlberg C; Vrang L; Sedig S; Hamelink E; Henderson I; Agback T; Jansson K; Borkakoti N; Derbyshire D; Eneroth A; Samuelsson B
Bioorg Med Chem Lett; 2011 Jan; 21(1):358-62. PubMed ID: 21112780
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and optimization of novel (3S,5R)-5-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)piperidine-3-carboxamides as orally active renin inhibitors.
Mori Y; Ogawa Y; Mochizuki A; Nakamura Y; Fujimoto T; Sugita C; Miyazaki S; Tamaki K; Nagayama T; Nagai Y; Inoue S; Chiba K; Nishi T
Bioorg Med Chem; 2013 Sep; 21(18):5907-22. PubMed ID: 23886807
[TBL] [Abstract][Full Text] [Related]
19. C-terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties.
Boyd SA; Fung AK; Baker WR; Mantei RA; Armiger YL; Stein HH; Cohen J; Egan DA; Barlow JL; Klinghofer V
J Med Chem; 1992 May; 35(10):1735-46. PubMed ID: 1588555
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases.
Maibaum J; Rich DH
J Med Chem; 1988 Mar; 31(3):625-9. PubMed ID: 3126296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
